Innovent Reports P-III Study (ORIENT-31) Results of Sintilimab for EGFR-TKI Failed EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shots:
- The 2nd interim analysis & survival analysis results from the P-III study evaluating sintilimab with/out bevacizumab + CT vs CT (Arm C) in 600 patients
- As of the data cutoff date of Mar 2022, the median follow-up duration of PFS was 12.9/15.1/14.4mos. in Arm A {(sintilimab + bevacizumab & CT)/B (sintilimab + CT) /C)}; m-PFS based on the assessment by IRRC (7.2/5.5/4.3mos.), improvement in PFS in Arm B which reached the pre-specified superiority boundary value & PFS benefit was sustained in Arm A vs Arm C
- As of data cutoff July 2022, OS benefits in Arms A & m-OS were 21.1mos. in Arm A vs 19.2mos. in Arm C, TRAEs of grade ≥3 in Arm A/B/C (56%/41%/49%). The results were published in the Lancet Respiratory Medicine
Ref: PRnewswire | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
